Brief: Lipigon and HitGen Announce Achievement Of Important Milestone In Dyslipidemia Project
21/03/2022 07:34
March 21 (Reuters) - Lipigon Pharmaceuticals AB LPGO.ST :
* CO AND HITGEN HAVE IDENTIFIED NOVEL SMALL MOLECULES THAT
COULD
BE STARTING POINTS FOR DEVELOPING DRUGS TARGETING DYSLIPIDEMIA
AND CARDIOVASCULAR DISEASE.
Source text for Eikon: ID:nBQN8JVTN4
Further company coverage: LPGO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Lipigon Pharmaceuticals AB
See all newsBrief: Nasdaq To Delist Lipigon Pharmaceuticals From First North Growth Market
Brief: Lipigon Expected To Be Removed From Trading On Nasdaq Stockholm On May 18
Brief: Lipigon Proposes To Delist Company From Nasdaq First NGM
Brief: Lipigon Pharmaceuticals Oct-Dec Oper Loss At SEK 7.2 Mln
Brief: Lipigon Pharmaceuticals Aims To Reduce Cost Base By Two-Thirds